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ABSTRACT
Bisphosphonates are bone-turnover modulating drugs which are used in the management of a number of bone diseases 
ranging from osteoporosis to neoplasic pathology-associated osteolysis. In the last years a number of cases of osteonecrosis 
of the jaws associated with these drugs have been reported. In this review we analyze the cases published in the literature 
indexed from 2003 to December 2005. During this period 246 cases were reported, being more frequently associated with 
women in the sixth decade of life. More frequently associated bisphosphonates were the nitrogenated bisphosphonates 
(pamidronate, zolendronic acid) and the most common oral antecedent was a dental extraction. Nevertheless more than 
25% of the cases were spontaneous. The most frequent site was the mandible and most of the cases presented clinical 
evidence of bone exposure and pain. Different treatments have been proposed with different antibiotic therapies with 
or without surgery, showing in general terms an uncertain prognosis with low healing rates.
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RESUMEN
Los bisfosfonatos son fármacos moduladores del recambio óseo que están indicados en numerosas patologías óseas 
desde la osteoporosis a la osteolisis asociada a patología neoplásica. En los últimos años se han ido publicando nume-
rosos casos de osteonecrosis de los maxilares asociada a la toma de estos medicamentos. En esta revisión se analizan 
los casos publicados en la literatura indexada desde el inicial del 2003 hasta diciembre del 2005. Durante este periodo 
se han publicado 246 casos, afectando más a las mujeres y sobre todo en la sexta década de vida. Los bisfosfonatos más 
frecuentemente asociados han sido los nitrogenados (pamidronato-ácido zoledrónico) y el antecedente oral más común 
la exodoncia. No obstante, más del 25% correspondieron a casos “espontáneos”. La localización mas frecuente fue la 
mandíbula y clínicamente la mayoría de los casos mostraban exposición ósea y dolor asociado. La terapéutica ha sido 
muy diversa con diferentes pautas antibióticas con o sin cirugía, mostrando en general un pronóstico incierto con bajos 
índices de curación.
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INTRODUCTION
The first case of osteonecrosis of the jaws (ONJ) associated 
with bisphosphonate (BPP)-therapy was reported by Marx 
in 2003 (1). Since then a number of new cases have been 
reported, isolated or in series, which has now become a 
“growing epidemic” (1).
In the present review we have gathered the cases indexed in 
MEDLINE database, from the first one in 2003 made by 
Wang et al (2) to the one made at the end of 2005 by Merigo 
et al (3) which makes a total of 246 cases.
The first author to associate ONJ with BPP was Marx 
(1). However, the first description of BPP associated ONJ 
was made by Wang et al (2), but was initially attributed to 
chemotherapy received by these patients. At a later time, 
when similar cases were reported, it was concluded that the 
osteonecrosis could be caused by BPP. (4)
Last year 2005, Marx et al. (5) published a review on this 
subject with a wide number of cases in which his own case as 
well as those derived by colleagues were analyzed, including 
also cases that had already been published.
In this review we have gathered 246 cases of scientific litera-
ture indexed and have divided them into Group A with 127 
cases obtained from different studies (2, 3, 6-16) and Group 
B with the 119 cases reported by Marx et al. (5). In each of 
the sections, both groups were analyzed separately as it was 
not possible to form one group due to lack of important 
data in some of the articles.
REVIEW
1.- In relation to the age and sex
In Group A (N=127) 85 cases (66.9%) corresponded to 
female and 42 (33.1%) to male patients. In this group the 
relationship female-male was almost 2:1.
The average age in Group A at the moment of diagnosis 
of the ONJ was 65.6 years, with a minimum of 36 and a 
maximum of 89 years. The average age of female patients 
was 65.3 years (range 36-89) and 66.1 years (range 45-85) 
for the male patients.
Surprisingly in the review presented by Marx et al. (Group 
B) (5) no references appear related to sex or the age of the 
patients.
2.- In relation to the type of BPP and the previous pathology
From the different types of BPP associated with ONJ in 
Group A (N=127), the most common was pamidronate in 
54 patients (42.5%), followed by the combination of pami-
dronate and zolendronic acid in 31 (24.4%) and zolendronic 
acid in 29 (22.8%). Alendronate was associated with 9 pa-
tients (7.1%) and ibandronate and risedronate in 1 patient 
(0.8%) respectively. The combination of alendronate and 
zolendronic acid was used in 2 patients (1.6%).
The main data concerning patients of Group A who took 
alendronate are shown in Table 1.
In Group B (5) the most frequently associated BPP was 
zolendronic acid in 40.3% of the patients, followed by tho-
se who started their treatment with pamidronate and then 
changed to zolendronic acid in 30.2%, 26% of the patients 
with pamidronate and 2.5% with alendronate.
Table 1. Characteristics of ONJ patients associated to alendro-
nate therapy. 
(References: 6, 11, 12, 14)
ONJ: osteonecrosis of the jawsr/BPP: bisphosphonate                         
* (N=8)
ONJ-BPP breast cancer 
(N=50)
Sex 50 female (100%)  
Middle age 61.7 years (range 36-89).  
Pamidronate  25 (50%) 
Zoledronic acid  13 (26%) 
Pamidronate & zolendronic  10 (20%) 
Ibandronate  1 (2%) 
Type of BPP




Middle time           18.3 months  
                                           (range 5-48) 
Mandible   24 (48%) 
Upper maxillary  15 (30%) 
Localization 
ONJ
Mandible & Maxillary 11 (22%) 
Nine   14 (51.9) Previous oral 
intervention 
(N=27) Dental extraction                 13 (48.1%) 
Table 2. Characteristics of the group of patients with breast cancer 
and ONJ associated to BPP therapy. 
ONJ-BPP breast cancer 
(N=50)
ONJ: osteonecrosis of the jaws/BPP: bisphosphonate
ONJ-Alendronate
(N=9)
Sex 8 female: 1 male 
Middle age 71.6 years (range 58-84) 
Osteoporosis 7 (77.8%) 
Breast cancer 1 (11.1%) 
Pathology
associated
Paget´s disease 1 (11.1%) 
Time therapy
BPP >ONJ
Middle time         44.2 months  
                          (range 25-60) 
Mandible  6 (66.7%) 
Upper maxillary  3 (33.3%) 
Bilateral  1 (12.5%)* 
Localization 
ONJ
Unilateral  7 (87.5%)*  
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In Group A (N=127) therapy with BPP was used in the ma-
nagement of multiple myeloma in 53 patients (41.7%) and 
breast cancer in 50 (39.4%). It was also used in osteoporosis 
in 10 patients (7.9%),in prostate cancer in 8 cases (6.3%), 
Paget’s disease in 3 patients (2.4%), in 2 patients with me-
tastatic lung cancer (1.6%) and in 1 case of uterine sarcoma 
(0.8%).
The main data concerning the characteristics of the groups 
of  patients with breast cancer, multiple myeloma and 
osteoporosis in Group A are shown in Tables 2, 3 and 4.
In Group B (5) the most frequent pathologies were multi-
ple myeloma (52.1%) and breast cancer (42%) followed by 
prostate cancer (3.4%) and osteoporosis (2.5%).
3.- In relation to treatment duration before the ONJ ap-
peared
In Group A (N=100) the average time of treatment with BPP 
before the appearance of the ONJ was 19.9 months (range 
5-79). In those patients under treatment with the combina-
tion of zolendronic acid and pamidronate (27 cases), the 
average time of the therapy was 25.8 months (range 9-79), 
for zolendronic acid (24 cases)  16.9 months (range 5-36) and 
for pamidronate (45 cases) 15.5 months (range 6-72). In the 
patients taking alendronate the time was only specified in 4 
cases, the average being 44.2 months (range 25-60).
In Group B (5) the average time in patients taking zolen-
dronic acid was 9.4 months. In those patients who began 
their therapy with pamidronate and then changed to zo-
lendronic acid it was 12.1 months, 14.3 months for those 
treated with pamidronate and 36 months for the patients 
taking alendronate.
4.- In relation to the odontologic antecedent and the lo-
cation
In Group A (N=124) the ONJ appeared in 87 cases after a 
dental extraction (71.3%), without a known oral antecedent 
(“spontaneous”) in 35 cases (28.7%), caused by a denture 
in 1 case (0.8%) and after the surgical removal of implants 
in another case (0.8%).
In Group B (5) the most frequent antecedent was a dental 
extraction (37.8%), followed by periodontal disease (28.6%) 
and was spontaneous in 25.2% of the cases. Other antece-
dents named were periodontal surgery (4.2%), implanta-
tion surgery (3.4%) and 1 case associated with apicectomy 
(0.8%).
As to the site of the lesions in Group A (N=127) in 69 cases 
(54.3%) they appeared in the mandible, in 37 cases in the 
maxilla (29.1%) and in 21 patients (16.5%) both jaws were 
affected. In 94 cases when specified, the ONJ was unilateral 
in 86 cases (91.5%) and bilateral in 8 (8.5%).
In Group B (5) 68.1% of ONJ developed in the lower jaw, 
27.7% in the upper jaw and only in 4.2% of the patients 
were both jaws affected.
5.- In relation to clinical aspects
The clinical forms of presentation of ONJ associated with 
BPP described in literature are diverse and in each case 
there are different clinical items combined, sometimes very 
extensively and some other times not so extensively.
In the analysis of Group A we excluded 58 of the 63 cases 
ONJ-BFF multiple myeloma 
(N=53)
Sex 23 female: 30 male  
Middle age 66.2 years (range 40-87).  
Pamidronate  22 (41.5%) 
Zoledronic acid  11 (20.7%) 
Pamidronate+Zoledronic 19 (35.8%) 
Type of  BPP
Alendronate+Zoledronic 1 (1.9%) 
Time therapy 
BPP>ONJ
Middle time              19.3 months  
                                            (range 12-72) 
Mandible   33 (62.3%) 
Upper maxillary  12 (22.6%) 
Localization 
ONJ
Mandible & Maxillary  8 (15.1%) 
Nine    7 (33.3%) Previous oral 
intervention 
(N=21) Dental extraction                 14 (66.7%) 
Table 3. Characteristics of the group of patients with multiple mye-
loma and ONJ associated to BPP therapy.  
ONJ: osteonecrosis of the jaws/BPP: bisphosphonate
ONJ-BPP osteoporosis 
(N=10)
Sex 8 female: 2 male 
Middle age 71 years (range 45-82).  
Alendronate  7 (70%) 
Alendronate+zoledronic 1 (10%) 
Pamidronate+zoledronic 1 (10%) 
Type of  BPP




Middle time             40 months  
                                         (range 12-79) 
Mandible                  8 (80%) 
Localization
Upper maxillary                 2 (20%) 
Nine   1  




Oral surgery  1 
Table 4. Characteristics of the group of patients with osteoporosis 
and ONJ associated to BPP therapy.  
ONJ: osteonecrosis of the jaws/BPP: bisphosphonate
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from the article of Ruggiero et al (11) as the form of pre-
sentation of the pathology was not clearly specified.
In Group A (N=69) the most common data was the presen-
ce of an exposed area of bone which appeared in 52 cases 
(75.4%), followed by pain in 22 patients (31.9%). Other 
clinical manifestations were pathologic fractures in 8 cases 
(7.2%), non-healing sockets in 6 (8.7%), suppuration in 4 
(5.8%), NOS ulcers (inespecific) in 6 (8.7%), swelling in 3 
(4.3%) and maxillar sinusitis in 1 case (1.4%). In 15 other 
cases (21.7%) other signs were described such as: oroantral 
fistula, bone sequestrum, soft tissue lesions, osteolytic le-
sions, paresthesia, infection and skin fistula.
In Group B (5), the most frequent clinical manifestation 
was bone exposition associated with pain in 68.9% of the 
patients. Nevertheless, Marx et al. (5) noted that in 31.1% 
of the cases the exposed bone was asymptomatic and was 
a casual finding in a routine oral exploration. In this group 
23.5% of the patients presented one or more mobile teeth 
and in 17.6% there was skin or mucosa fistula and even 
exposed bone through the skin.
6.- In relation to the treatment and the prognosis
In Group A the treatment was completely specified in 102 
cases, explaining the procedures and the drugs used. In this 
group 80 cases (78.4%) were treated with antibiotics and 
minor oral surgery and 22 (21.6%) with antibiotic therapy 
and radical oral surgery. In 3 cases (2.9%) only antibiotic 
therapy was given and in 4 cases hiperbaric oxygen was also 
administered (3.9%).
In relation to the type of antibiotic used, some authors (6) 
advised penicillin, while others used amoxicillin exclusi-
vely (7) either in combination with clavulanic acid (9) or 
metronidazol (12). In allergic patients the alternative to 
amoxicillin was clindamicin (7, 9). On the other hand, Me-
rigo et al (3) combined cefallosporines and metronidazol in 
conjunction with antifungic drugs (fluconazol), as in 2 pa-
tients Candida albicans was found. Throndson et al (13) used 
different antibiotic therapies with penicillin and other beta-
lactamics, tetraciclines, doxicicline and/or eritromicine.
Regarding surgery, among the minor surgey to be included 
are sequestrectomy, practiced in 59 cases (73.7%), debride-
ment or local resection in 17 cases (21.2%) and curetage in 
6 cases (7.5%).
More radical surgery consisted of: mandibular decortica-
tion in 1 case (4.5%), marginal mandibulectomy in 4 cases 
(18.2%), segmentary or partial maxilectomy or mandibu-
lectomy in 13 cases (59.1%) and total maxillectomy in 4 
cases (18.2%).
In Group B Marx et al. (5) expounds as a general therapy 
the administration of  a long-term or even a permanent 
antibiotic therapy, based on penicillin V-K (500 mg oral, 
4 times a day) as well as mouthwashes with clorhexidine 
0.12%. In refractory cases or those with a more serious 
symptomatology, metronidazol (500 mg oral 3 times a 
day) should be added. If  a severe celulitis develops hos-
pitalization it’s necessary and intravenous ampicillin with 
metronidazol should be given. In patients with penicillin 
allergy metronidazol should be given (500 mg oral 3 times 
a day), combined with ciprofloxacin (500 mg oral twice a 
day) or combined with eritromicine (400 mg oral 3 times a 
day). This author (5) does not recommend surgery in the 
treatment of these cases.
In Group A the results of the treatment used were only 
shown in 14 cases. In 5 patients (35.7%) a total success was 
obtained, in 5 (35.7%) a partial success was obtained and 
in the 4 last cases (28.6%) the treatment failed. In 3 cases 
treatment with minor surgery was a total success and in the 
other 2 cases with major surgery. The cases of partial success 
were treated with antibiotics in 2 cases, minor surgery in 2 
cases and minor surgery combined with hiperbaric oxygen 
in 1 case. The patients where treatment failed had been ma-
naged with minor surgery in 2 cases, hiperbaric oxygen in 1 
case and major surgery combined with hiperbaric oxygen 
in another case.
In the review presented by Marx et al. (5) of the 91 cases 
treated only with antibiotics, in 9 (9.9%) an intermittent 
pain persisted; that required dose adjustments or the adding 
more antibiotics. However, in the other 82 cases (90.1%) the 
patients had no pain and a change in antibiotherapy was not 
necessary. None of the patients had jaw fractures.
DISCUSSION
The ONJ has become over the last years a frequent  and 
important pathology in patients with diverse bone systemic 
disorders treated with BPP therapies. (1, 5, 8, 9, 11, 17).
In the review of the cases which appeared in the literature 
indexed between 2003 and 2005 ONJ associated with BPP 
is much more frequent in female patients. This could be ex-
plained by the fact that these drugs are used more frequently 
in women as is the case with postmenopausic osteoporosis 
and breast cancer.
Also, the fact that this group of patients had a higher ave-
rage age would be related to the age at which this disease, 
in which the BPP are more frequently used, appear which 
usually corresponds to people with more than 55 years. Ne-
vertheless, there are cases of ONJ-BPP described in young 
people (<40 years), which would indicate this pathology is 
not age-dependent (8, 9).
In the analysis of the literature it is clearly recognized that 
the nitrogenated BPP, of  parenteral administration and 
high activity (pamidronate and zolendronic acid), are the 
BPP most commonly associated with ONJ. However, there 
are also cases associated with other BPP of oral adminis-
tration, including alendronate, but of a scarce frequency 
(6, 11, 12, 14).
The pathologies most frequently associated with ONJ-BPP 
were multiple myeloma and breast cancer, that together 
represent more than 80%. This would not be unexpected 
because these two diseases usually receive treatment with 
parenteral high activity BPP, preferentially pamidronate 
and zolendronic acid.
The ONJ appears earlier in patients treated with parenteral 
BPP such as zolendronic acid and pamidronate than in 
others such as alendronate. Also, it can be concluded from 
the review that as the treatment time increases, the possibility 
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of suffering this disorder increase as well. However we think 
that the ONJ apparition is related preferentially to the time 
when the predisposing oral lesion is produced, for example 
a tooth extraction, than with the real treatment time.
In both groups it can be seen that even though the dental 
extraction is the most frequent cause of oral antecedent, 
other odontologic factors can cause the development of 
ONJ. Also, it should be noticed that in both groups 25% of 
the cases were diagnosed with no confirmed oral antecedent, 
that is, they were “spontaneous cases”. Nevertheless, the oral 
cavity is constantly exposed to traumatic situations, subjecti-
vely imperceptible, which in a normal mouth would not give 
rise to any disorder but that in this anormal condition any 
tisular laceration can become the initiating factor of ONJ.
As would be expected, the jaw has been the most frequent 
location of ONJ in both groups of patients. It is known 
that mandibular bone has anatomic and physiologic featu-
res that would give rise to the apparition of osteonecrotic 
pathology (18).
We do not know why in Group A there are more cases of 
ONJ affecting both jaws than in Group B, although it could 
be because the diagnosis was made later, giving time for 
more serious lesions to develop.
Regarding antibiotic therapy there is no agreement con-
cerning the cases described in the literature and different 
therapies have been used, usually with long-term wide 
spectrum antibiotics such as: amoxicillin with or without 
clavulanic acid, cefallosporins, metronidazol, macrolids, 
etc., alone or combined. Marx et al. (5) advocated the use of 
oral amoxicillin combined with clorhexidine mouthwashes, 
a therapy with good results. However, this antibiotic therapy 
needs to be strictly followed and sometimes it is very difficult 
to finish the treatment. The most common alternative to 
penicillin derived drugs is clindamicine (7, 9). Nevertheless, 
some authors (5) are against the use of clindamicine as its 
low activity versus Actynomices, Eikenella corrodens and 
other similar species that appear in these cases.
Regarding surgical treatment, Marx et al. (5) does not re-
commend surgery in the treatment of ONJ-BPP, because 
he considers that attempts to make debridements, covering 
exposed areas with flaps or remodelation of bone usually 
are counter-productive. For this author (5), these procedu-
res can lead to a greater amount of exposed bone with a 
worsening of symptoms and a greater risk of a jaw fractu-
re. He only recommends surgery in those refractory cases 
to non-surgical treatment and if  sypmtoms continue. He 
considers that in BPP-induced bone exposures, the whole 
bone is affected thus it is not possible to find a viable bone 
margin. For Marx et al. (5), these patients can and must 
live with some exposed bone and treatment should be ai-
med at eliminating or controlling pain and preventing the 
progression of lesions. The exposed necrotic bone itself  is 
not painful and will maintain its structure for normal jaw 
function. However if  it becomes infected secondary pain 
starts and celulitis and fistula formation could appear. 
Pathologic fractures are not common unless debridement 
surgery has reduced the jaw’s structural integrity. For this 
author (5), debridement surgery is not to be recommended 
except where there is softening of bony sharp projections 
causing inflammation and pain.
Concerning the prognosis, only in Marx’s et al.  review (5) 
can we see good results if  we consider that 90% of the pa-
tients were controlled only with antibiotic therapy. In the 
rest of the cases, the scarce data do not show that surgery 
or the use of other techniques such as hiperbaric oxygen 
are the main elements in the prognosis.
All this supports the fact of the need to establish preventive 
measures in all the patients treated with BPP to prevent this 
osteonecrotic pathology of the jaws.
Oral Medicine and Pathology                                                                                                                                                                                                               Med Oral Patol Oral Cir Bucal 2006;11:E456-61.                                                          Oral Medicine and Pathology                                                                               � Med Oral Patol Oral Cir Bucal 2006;11:E456-61.  
E461
© Medicina Oral S.L. Email: medicina@medicinaoral.com
REFERENCES
1. Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced 
avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 
2003;61:1115-7.
2.  Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated 
with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
3. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone 
necrosis without previous  dental extractions associated with the use of 
bisphosphonates (pamidronate and zolendronate): a four-case report. J 
Oral Pathol Med 2005;34:613-7.
4. Robinson NA, Yeo JF. Bisphosphonates – a word of caution. Ann Acad 
Med Singapore 2004;33:48-9.
5. Marx RE, Sawatari Y, Fortín M, Broumand V. Bisphosphonate-indu-
ced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, 
recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63: 
1567-75
6. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis 
of the jaw: a possible association. Med J Aust 2005;182:413-5.
7. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, 
Gundlach KK. Does avascular necrosis of the jaws in cancer patients only 
occur following treatment with bisphosphonates?. J Craniomaxillofac 
Surg 2005;33:395-403.
8. Bagán JV, Jiménez Y, Murillo J, Hernández S, Poveda R, Sanchís JM et 
al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed 
areas and its relationship to teeth extractions. Study of 20 cases. Oral 
Oncol 2006;42:327-9.
9. Bagán JV, Murillo J, Jiménez Y, Poveda R, Milian MA, Sanchís JM et 
al. Avascular jaw osteonecrosis in association with cancer chemotherapy: 
series of 10 cases. J Oral Pathol Med 2005;34:120-3
10. Katz H. Endodontic implications of  bisphosphonate-associated 
osteonecrosis of the jaws: a report of three cases. J Endod 2005;31:831-4.
11. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of 
the jaws associated with the use of bisphosphonates: a review of 63 cases. 
J Oral Maxillofac Surg 2004;62:527-34.
12. Najm SA, Lysitsa S, Carrel JP, Lesclous P, Lombardi T, Samson J. 
Ostéonécrose des maxillaires chez des patients traités par bisphosphonates. 
Presse Med 2005;34:1073-7.
13. Throndson RR, Healy SM, Zwickey MR. Bisphosphonate-induced 
osteonecrosis of the jaws. Tex Dent J 2005;122:960-5.
14. Sitters MA, Caldwell CS. Bisphosphonates, dental care and 
osteonecrosis of the jaws. Tex Dent J 2005;122:968-72.
15.  Junod AF, Carrel JP, Richter M, Vogt-Ferrier N. Ostéonécrose des 
maxillaires et bisphosphonates. Rev Med Suisse 2005;1:2537-40.
16. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of  jaw in patient 
with hormone-refractory prostate cancer treated with zolendronic acid. 
Urology 2005;66:658.
17. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez 
A, Sebastián-López C. Osteonecrosis maxilar y bisfosfonatos. Presentación 
de tres nuevos casos. Med Oral Patol Oral Cir Bucal 2006;11:76-9.
18. Marx R. Osteoradionecrosis: a new concept of its pathophysiology. J 
Oral Maxillofac Surg 1983;41:283-8.
Acknowledgements: We want to thank to Mr. David Hallett for revising 
the English language in this paper.
